Overview

Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to collect information on the safety, especially localized injection site reactions, and efficacy of ORENCIA Subcutaneous Injection 125mg Syringe 1mL in patients with rheumatoid arthritis.
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Ono Pharmaceutical Co. Ltd
Treatments:
Abatacept